AbbVie’s skin disease drug posts Phase III win as market competition heats up
AbbVie's lutikizumab met primary endpoints in Phase III INTREPID trial for hidradenitis suppurativa (HS), reducing flares and skin pain. 31.4% of patients achieved HiSCR75 vs. 23.4% on placebo. Analysts noted response rates were lower than expected, but AbbVie highlights the drug's potential. Competitors include Novartis' Cosentyx and UCB's Bimzelx. HS market projected to grow to $7.8bn by 2034, according to GlobalData.
How this was made
The 30-second read
Why it matters
The modest efficacy may delay or limit commercial rollout, affecting AbbVie's pipeline expectations and valuation.
Market read
Primary disclosure of Phase III data for a large‑cap biotech; relevant for investors tracking dermatology biologics.
What to watch
Long‑term safety profile appears clean; future data on HiSCR50/90 and biologic‑exposed subpopulations could improve outlook.
Background
AbbVie’s existing HS treatment Humira faces competition from Novartis’ Cosentyx and UCB’s Bimzelx. The INTREPID trial is the first Phase III data for an IL‑1α/β antagonist in this indication.
Ticker impact
AbbVie reported Phase III INTREPID trial results for its hidradenitis suppurativa drug lutikizumab, showing modest efficacy versus placebo.
likely slight downside pressure as investors reassess the drug's commercial potential
The trial met its primary endpoint but the placebo‑adjusted response was well below analyst expectations, suggesting limited near‑term revenue upside.
Market effects
The result may slow momentum for IL‑1 targeting therapies in the broader dermatology/auto‑immune space.
U.S. biotech sector could see modest pullback pending further data on similar candidates.
Limited to companies developing biologics for skin diseases; no immediate global macro effect.
Counterpoint
If the drug eventually gains approval, its differentiated mechanism could capture market share from existing HS biologics.
Key entities
- CompanyAbbVie
Pharmaceutical company developing lutikizumab for hidradenitis suppurativa.
- CompanyNovartis
Competitor with Cosentyx, a leading HS therapy.
